Ziftomenib；KO539

Non chimik:

(S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin -1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indol-2-karbonitrile

Kòd SMILES:

N#CC(N1C[C@@H](N2CCN(S(=O)(C)=O)CC2)C)=CC3=C1C=CC(CN4CCC(NC5=C(C=C(CC(F))) (F)F)S6)C6=NC(NC)=N5)CC4)=C3C

Kòd InChi:

InChI=1S/C33H42F3N9O2S2/c1-21(43-11-13-44(14-12-43)49(4,46)47) 19-45-25(18-37)15-27-22(2)23(5-6-29(27)45)20-42-9-7-24(8-10-42) )39-30-28-16-26(17-33(34,35)36)48-31(28)41-32(38-3)40-30/h5-6, 15-16,21,24H,7-14,17,19-20H2,1-4H3,(H2,38,39,40,41)/t21-/m0/s1

InChi kle:

BGGALFIXXQOTPY-NRFANRHFSA-N

Mot:

2134675-36-6；CAS:2134675-36-6；CAS:2134675-36-6；Ziftomenib; KO539; KO 539; KO-539

Solibilite:Pou detèmine

Depo:Sèk, nwa ak nan 0 - 4 C pou kout tèm (jou a semèn) oswa -20 C pou tèm long (mwa a ane).

Deskripsyon:

Ziftomenib (KO-539) se yon inibitè nan menin MLL entèraksyon ak aktivite oral.

Sib: menin-MLL